September 10, 2025CureusOpen Access

Effects of Dapagliflozin vs. Vildagliptin on the Lipid Profile of Patients With Uncontrolled Type 2 Diabetes

View Full Paper

Ask AI

Bookmark

Dapagliflozin improved HDL-C by 3.17 mg/dL in patients with type 2 diabetes, indicating potential cardiovascular benefits.
Vildagliptin led to a significant reduction in LDL-C levels by 11.8 mg/dL compared to dapagliflozin, suggesting a preference for elevated LDL-C patients.
No significant differences in HbA1c and other lipid measures were observed between the two drug groups after 24 weeks of therapy.
Both drugs improved glycemic control and favorably influenced lipid profiles, which may ultimately reduce ASCVD risk.

Discussion

No takes yet. Share an insight, caveat, or question.

Observational study compares effects on lipid profiles and glycemic control in T2D patients, indicating varied benefits.

Khanna et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark